Common variants of the vitamin D binding protein gene and adverse health outcomes

Critical Reviews in Clinical Laboratory Sciences

Volumn 50, Issue 1, 2013, Pages 1-22

  Malik, Suneil ^a   Fu, Lei ^b,c   Juras, David James ^a   Karmali, Mohamed ^a   Wong, Betty Y L ^b   Gozdzik, Agnes ^d   Cole, David E C ^b,c,d  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b Institute of Clinical Evaluative Sciences   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Association studies; Cancer; Chronic and infectious diseases, common polymorphisms; GC gene; Inflammation; Vitamin D binding protein macrophage activating factor; Vitamin D binding protein group specific component Gc globulin

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D BINDING PROTEIN;

ADVERSE OUTCOME; AMYOTROPHIC LATERAL SCLEROSIS; ASTHMA; AUTOIMMUNE THYROIDITIS; BASAL CELL CARCINOMA; BRAIN ISCHEMIA; BREAST CANCER; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; ENDOMETRIOSIS; ENTERITIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LIVER DISEASE; MISSENSE MUTATION; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATIC FEVER; SARCOIDOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; TUBERCULOSIS; VITAMIN D METABOLISM;

DISEASE; GENETIC PREDISPOSITION TO DISEASE; HEALTH; HUMANS; IMMUNITY, INNATE; MUTATION; VITAMIN D-BINDING PROTEIN;

EID: 84875046854     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2012.750262     Document Type: Review

References (227)

1. Haddad JG, Hu YZ, Kowalski MA, et al. Identification of the sterol-and actin-binding domains of plasma vitamin D binding protein (Gc-globulin). Biochemistry 1992;31:7174-81.
2. Otterbein LR, Cosio C, Graceffa P, Dominguez R. Crystal structures of the vitamin D-binding protein and its complex with actin: structural basis of the actin-scavenger system. Proc Natl Acad Sci USA 2002;99:8003-8.
3. Verboven C, Rabijns A, De MM, et al. A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol 2002;9:131-6.
4. Zhang J, Habiel DM, Ramadass M, Kew RR. Identification of two distinct cell binding sequences in the vitamin D binding protein. Biochim Biophys Acta 2010;1803:623-9.
5. Bouillon R, Van BH, Rombauts W, De MP. The purification and characterisation of the human-serum binding protein for the 25- hydroxycholecalciferol (transcalciferin). Identity with groupspecific component. Eur J Biochem 1976;66:285-91.
6. Daiger SP, Schanfield MS, Cavalli-Sforza LL. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci USA 1975;72:2076-80.
7. Meier U, Gressner O, Lammert F, Gressner AM. Gcglobulin: roles in response to injury. Clin Chem 2006; 52:1247-53.
8. Bouillon R, Xiang DZ, Convents R, Van BH. Polyunsaturated fatty acids decrease the apparent affinity of vitamin D metabolites for human vitamin D-binding protein. J Steroid Biochem Mol Biol 1992;42:855-61.
9. Calvo M, Ena JM. Relations between vitamin D and fatty acid binding properties of vitamin D-binding protein. Biochem Biophys Res Commun 1989;163:14-7.
10. Ena JM, Esteban C, Perez MD, et al. Fatty acids bound to vitamin D-binding protein (DBP) from human and bovine sera. Biochem Int 1989;19:1-7.
11. Van BH, Bouillon R, De MP. Vitamin D-binding protein (Gcglobulin) binds actin. J Biol Chem 1980;255:2270-2.
12. Williams MH, Van Alstyne EL, Galbraith RM. Evidence of a novel association of unsaturated fatty acids with Gc (vitamin D-binding protein). Biochem Biophys Res Commun 1988;153:1019-24.
13. Cho EH, Kim MR, Kim HJ, et al. The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. Proteomics Clin Appl 2007;1:352-61.
14. Pawlik TM, Hawke DH, Liu Y, et al. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 2006;6:68.
15. Bijian K, Mlynarek AM, Balys RL, et al. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J Proteome Res 2009;8:2173-85.
16. Wu Y, Shu R, Luo LJ, et al. Initial comparison of proteomic profiles of whole unstimulated saliva obtained from generalized aggressive periodontitis patients and healthy control subjects. J Periodontal Res 2009;44:636-44.
17. Xiao F, Chen D, Lu Y, et al. Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy. Brain Res 2009;255:180-9.
18. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008;129:526-9.
19. Duan X, Lu Q, Xue P, et al. Proteomic analysis of aqueous humor from patients with myopia. Mol Vis 2008;14:370-7.
20. Hattori N, Oda S, Sadahiro T, et al. YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock 2009;32:393-400.
21. Bai S, Liu S, Guo X, et al. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol Vis 2009;15:1638-48.
22. Greco M, Mitri MD, Chiriaco F, et al. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett 2009;283:222-9.
23. Chan KY, Lai PB, Squire JA, et al. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol 2006;19:1546-54.
24. Gressner OA, Gao C, Siluschek M, et al. Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2009;21:990-5.
25. Kim BK, Lee JW, Park PJ, et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 2009;11:R22.
26. Anagnostopoulos AK, Kolialexi A, Mavrou A, et al. Proteomic analysis of amniotic fluid in pregnancies with Klinefelter syndrome foetuses. J Proteomics 2010;73:943-50.
27. Blanton D, Han Z, Bierschenk L, et al. Reduced serum vitamin dbinding protein levels are associated with type 1 diabetes. Diabetes 2011;60:2566-70.
28. Song YH, Naumova AK, Liebhaber SA, Cooke NE. Physical and meiotic mapping of the region of human chromosome 4q11-q13 encompassing the vitamin D binding protein DBP/Gcglobulin and albumin multigene cluster. Genome Res 1999;9:581-7.
29. Hiroki T, Song YH, Liebhaber SA, Cooke NE. The human vitamin D-binding protein gene contains locus control determinants sufficient for autonomous activation in hepatic chromatin. Nucleic Acids Res 2006;34:2154-65.
30. Daiger SP, Miller M, Chakraborty R. Heritability of quantitative variation at the group-specific component (Gc) locus. Am J Hum Genet 1984;36:663-76.
31. Hunter D, De LM, Snieder H, et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 2001;16:371-8.
32. Constans J, Viau M. Group-specific component: evidence for two subtypes of the Gc1 gene. Science 1977;198:1070-1.
33. Van BH, Bouillon R, De MP. The heterogeneity of human Gc-globulin. J Biol Chem 1978;253:6344-5.
34. Lauridsen AL, Vestergaard P, Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem 2001;47:753-6.
35. Constans J, Arlet P, Viau M, Bouissou C. Unusual sialilation of the serum DBP associated with the Gc 1 allele in alcoholic cirrhosis of the liver. Clin Chim Acta 1983; 130:219-30.
36. Fu L, Cade C, Holm SS, et al. Relationship of functional T436K polymorphism in vitamin D binding protein (DBP) with serum 25-hydroxyvitamin D [25(OH)D], DBP concentration and binding capacity: a pilot study. Clin Chem 2010;56:A154.
37. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010;19:2739-45.
38. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010;376:180-8.
39. Borges CR, Jarvis JW, Oran PE, Nelson RW. Population studies of Vitamin D binding protein microheterogeneity by mass spectrometry lead to characterization of its genotypedependent O-glycosylation patterns. J Proteome Res 2008;7:4143-53.
40. Borges CR, Jarvis JW, Oran PE, et al. Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS. J Biomol Tech 2008;19:167-76.
41. Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005;77:15-22.
42. Lu L, Sheng H, Li H, et al. Associations between common variants in GC and DHCR7/NADSYN1 and vitamin D concentration in Chinese Hans. Hum Genet 2012;131:505-12.
43. Sinotte M, Diorio C, Berube S, et al. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009;89:634-40.
44. Fu L, Yun F, Oczak M, et al. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem 2009;42:1174-7.
45. National Cancer Institute. SNP500 cancer database. National Cancer Institute; 2010. Available from: http://variantgps.nci.nih.-gov/cgfseq/pages/ snp500.do [last accessed 22 Jan 2013].
46. Gozdzik A, Zhu J, Wong BY, et al. Association of vitamin D binding protein (VDBP) polymorphisms and serum 25(OH)D concentrations in a sample of young Canadian adults of different ancestry. J Steroid Biochem Mol Biol 2011;127:405-12.
47. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-57.
48. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
49. Feldman D, Pike JW, Adams JS. Vitamin D. 3rd ed. Amsterdam: Academic Press; 2011.
50. Bikle D. "Vitamin D system in mineral homeostasis". In: Singer F, ed. Disease of bone and mineral metabolism. Endotext.com, Available from: http://www.endotext.org/parathyroid/ index.htm.
51. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf) 2012;76:315-25.
52. Martineau AR, Wilkinson KA, Newton SM, et al. IFN-gamma-and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007;178:7190-8.
53. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.
54. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3.
55. Liu PT, Schenk M, Walker VP, et al. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 2009;4:e5810.
56. Binder R, Kress A, Kan G, et al. Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5amediated chemotaxis, degranulation and respiratory burst. Mol Immunol 1999;36:885-92.
57. Kew RR, Webster RO. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J Clin Invest 1988;82:364-9.
58. Kew RR, Fisher JA, Webster RO. Co-chemotactic effect of Gcglobulin (vitamin D binding protein) for C5a. Transient conversion into an active co-chemotaxin by neutrophils. J Immunol 1995;155:5369-74.
59. Piquette CA, Robinson-Hill R, Webster RO. Human monocyte chemotaxis to complement-derived chemotaxins is enhanced by Gc-globulin. J Leukoc Biol 1994;55:349-54.
60. Shah AB, DiMartino SJ, Trujillo G, KewRR. Selective inhibition of the C5a chemotactic cofactor function of the vitamin D binding protein by 1,25(OH)2 vitamin D3. Mol Immunol 2006;43:1109-15.
61. Yamamoto N, Homma S, Millman I. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 1991;147:273-80.
62. Yamamoto N, Kumashiro R, Yamamoto M, et al. Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin. Infect Immun 1993;61:5388-91.
63. Dahl B, Schiodt FV, Ott P, et al. Plasma concentration of Gcglobulin is associated with organ dysfunction and sepsis after injury. Crit Care Med 2003;31:152-6.
64. Haddad JG, Harper KD, Guoth M, et al. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA 1990;87:1381-5.
65. Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes 2010;3:173-86.
66. Pani MA, Donner H, Herwig J, et al. Vitamin D binding protein alleles and susceptibility for type 1 diabetes in Germans. Autoimmunity 1999;31:67-72.
67. Danescu LG, Levy S, Levy J. Vitamin D and diabetes mellitus. Endocrine 2009;35:11-7.
68. Hirai M, Suzuki S, Hinokio Y, et al. Variations in vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. J Clin Endocrinol Metab 2000;85:1951-53.
69. Szathmary EJ. The effect of Gc genotype on fasting insulin level in Dogrib Indians. Hum Genet 1987;75:368-72.
70. Baier LJ, Dobberfuhl AM, Pratley RE, et al. Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 1998;83:2993-96.
71. Iyengar S, Hamman RF, Marshall JA, et al. On the role of vitamin D binding globulin in glucose homeostasis: results from the San Luis Valley Diabetes Study. Genet Epidemiol 1989;6:691-8.
72. Hirai M, Suzuki S, Hinokio Y, et al. Group specific component protein genotype is associated with NIDDM in Japan. Diabetologia 1998;41:742-3.
73. Braun A, Bichlmaier R, Muller B, Cleve H. Molecular evaluation of an Alu repeat including a polymorphic variable poly(dA) (AluVpA) in the vitamin D binding protein (DBP) gene. Hum Genet 1993;90:526-32.
74. Klupa T, Malecki M, Hanna L, et al. Amino acid variants of the vitamin D-binding protein and risk of diabetes in white Americans of European origin. Eur J Endocrinol 1999;141:490-93.
75. Ye WZ, Dubois-Laforgue D, Bellanne-Chantelot C, et al. Variations in the vitamin D-binding protein (Gc locus) and risk of type 2 diabetes mellitus in French Caucasians. Metabolism 2001;50:366-69.
76. Malecki MT, Klupa T, Wanic K, et al. Vitamin D binding protein gene and genetic susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 2002;57:99-104.
77. Lauridsen AL, Vestergaard P, Hermann AP, et al. Female premenopausal fracture risk is associated with gc phenotype. J Bone Miner Res 2004;19:875-81.
78. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004;116:634-9.
79. Kuchuk NO, van Schoor NM, Pluijm SM, et al. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 2009;24:693-701.
80. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66.
81. Yamamoto N, Homma S. Vitamin D3 binding protein (groupspecific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 1991;88:8539-43.
82. Swamy N, Ghosh S, Schneider GB, Ray R. Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBPmaf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity. J Cell Biochem 2001;81:535-46.
83. Yamamoto N, Naraparaju VR, Orchard PJ. Defective lymphocyte glycosidases in the macrophage activation cascade of juvenile osteopetrosis. Blood 1996;88:1473-8.
84. Schneider GB, Benis KA, Flay NW, et al. Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations. Bone 1995;16:657-62.
85. Ezura Y, Nakajima T, Kajita M, et al. Association of molecular variants, haplotypes, and linkage disequilibrium within the human vitamin D-binding protein (DBP) gene with postmenopausal bone mineral density. J Bone Miner Res 2003;18:1642-49.
86. Papiha SS, Allcroft LC, Kanan RM, et al. Vitamin D binding protein gene in male osteoporosis: association of plasma DBP and bone mineral density with (TAAA)(n)-Alu polymorphism in DBP. Calcif Tissue Int 1999;65:262-6.
87. Aloanzi ZH, Tuck SP, Mastana SS, et al. Vitamin D-binding protein gene microsatellite polymorphism influences BMD and risk of fractures in men. Osteoporos Int 2008;19:951-60.
88. Fang Y, van Meurs JB, Arp P, et al. Vitamin D binding protein genotype and osteoporosis. Calcif Tissue Int 2009;85:85-93.
89. Schellenberg D, Pare PD, Weir TD, et al. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998;157:957-61.
90. Horne SL, Cockcroft DW, Dosman JA. Possible protective effect against chronic obstructive airways disease by the GC2 allele. Hum Hered 1990;40:173-6.
91. Kueppers F, Miller RD, Gordon H, et al. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med 1977;63:336-42.
92. Wood AM, Bassford C, Webster D, et al. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax 2011;66:205-10.
93. Ito I, Nagai S, Hoshino Y, et al. Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest 2004;125:63-70.
94. Ishii T, Keicho N, Teramoto S, et al. Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis. Eur Respir J 2001;18:753-7.
95. Shen LH, Zhang XM, Su DJ, et al. Association of vitamin D binding protein variants with susceptibility to chronic obstructive pulmonary disease. J Int Med Res 2010;38:1093-8.
96. Nagasawa H, Uto Y, Sasaki H, et al. Gc protein (vitamin Dbinding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res 2005;25:3689-95.
97. Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010;65:215-20.
98. Kasuga I, Pare PD, Ruan J, et al. Lack of association of group specific component haplotypes with lung function in smokers. Thorax 2003;58:790-3.
99. Sandford AJ, Chagani T, Weir TD, et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001;163:469-73.
100. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999;402:B12-17.
101. Litonjua AA, Weiss ST. Is vitamin D deficiency to blame for the asthma epidemic? J Allergy Clin Immunol 2007;120:1031-5.
102. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78.
103. Hollams EM, Hart PH, Holt BJ, et al. Vitamin D and atopy and asthma phenotypes in children: a longitudinal cohort study. Eur Respir J 2011;38:1320-7.
104. Pinto JM, Schneider J, Perez R, et al. Serum 25-hydroxyvitamin D levels are lower in urban African American subjects with chronic rhinosinusitis. J Allergy Clin Immunol 2008;122:415-7.
105. Freishtat RJ, Iqbal SF, Pillai DK, et al. High prevalence of vitamin D deficiency among inner-city African American youth with asthma in Washington, DC. J Pediatr 2010;156:948-52.
106. Hypponen E, Sovio U, Wjst M, et al. Infant vitamin d supplementation and allergic conditions in adulthood: northern Finland birth cohort 1966. Ann NY Acad Sci 2004;1037:84-95.
107. Wjst M, Hypponen E. Vitamin D serum levels and allergic rhinitis. Allergy 2007;62:1085-6.
108. Camargo Jr CA, Ingham T, Wickens K, et al. Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics 2011;127:e180-7.
109. Pillai DK, Iqbal SF, Benton AS, et al. Associations between genetic variants in vitamin D metabolism and asthma characteristics in Young African Americans: a pilot study. J Investig Med 2011;59:938-46.
110. Bosse Y, Lemire M, Poon AH, et al. Asthma and genes encoding components of the vitamin D pathway. Respir Res 2009;10:98.
111. Krstic G. Asthma prevalence associated with geographical latitude and regional insolation in the United States of America and Australia. PLoS One 2011;6:e18492.
112. Hughes AM, Lucas RM, Ponsonby AL, et al. The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. Pediatr Allergy Immunol 2011;22:327-33.
113. Annesi-Maesano I. Perinatal events, vitamin D, and the development of allergy. Pediatr Res 2002;52:3-5.
114. Gorman S, Judge MA, Burchell JT, et al. 1,25-Dihydroxyvitamin D3 enhances the ability of transferred CD4+ CD25+ cells to modulate T helper type 2-driven asthmatic responses. Immunology 2010;130:181-92.
115. Pichler J, Gerstmayr M, Szepfalusi Z, et al. 1 alpha,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr Res 2002;52:12-8.
116. Li F, Jiang L, Willis-Owen SA, et al. Vitamin D binding protein variants associate with asthma susceptibility in the Chinese Han population. BMC Med Genet 2011;12:103.
117. Wjst M, Altmuller J, Faus-Kessler T, et al. Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res 2006;7:60.
118. Pola R. Inflammatory markers for ischaemic stroke. Thromb Haemost 2009;101:800-1.
119. Wang X, Cheng S, Brophy VH, et al. A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke 2009;40:683-95.
120. Pilz S, Dobnig H, Fischer JE, et al. Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke 2008;39:2611-3.
121. Lobo R. Endometriosis: etiology, pathology, diagnosis, management. In: Katz Vea, ed. Comprehensive gynecology. 5th ed. Philadelphia: Mosby Elsevier; 2011:473-500.
122. Wellbery C. Diagnosis and treatment of endometriosis. Am Fam Physician 1999;60:1753-8.
123. Akoum A, Kong J, Metz C, Beaumont MC. Spontaneous and stimulated secretion of monocyte chemotactic protein-1 and macrophage migration inhibitory factor by peritoneal macrophages in women with and without endometriosis. Fertil Steril 2002;77:989-94.
124. Faserl K, Golderer G, Kremser L, et al. Polymorphism in vitamin D-binding protein as a genetic risk factor in the pathogenesis of endometriosis. J Clin Endocrinol Metab 2011;96:E233-41.
125. Eloranta JJ, Wenger C, Mwinyi J, et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011;21:559-64.
126. Mohr SB, Garland CF, Gorham ED, et al. Is ultraviolet B irradiance inversely associated with incidence rates of endometrial cancer: an ecological study of 107 countries. Prev Med 2007;45:327-31.
127. Mohr SB, Garland CF, Gorham ED, et al. Could ultraviolet B irradiance and vitamin D be associated with lower incidence rates of lung cancer? J Epidemiol Community Health 2008;62:69-74.
128. Porojnicu AC, Robsahm TE, Dahlback A, et al. Seasonal and geographical variations in lung cancer prognosis in Norway. Does vitamin D from the sun play a role? Lung Cancer 2007;55:263-70.
129. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990;19:820-4.
130. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999;8:399-406.
131. Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005;41:1164-9.
132. Reinhold U, Schmitz B, Kurbacher C, et al. Circulating 25-hydroxyvitamin D concentration in German cancer patients. Oncol Rep 2008;20:1539-43.
133. Agborsangaya CB, Surcel HM, Toriola AT, et al. Serum 25-hydroxyvitamin D at pregnancy and risk of breast cancer in a prospective study. Eur J Cancer 2010;46:467-70.
134. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
135. Colli JL, Colli A. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 2006;24:184-94.
136. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007;4:e103.
137. Colli JL, Grant WB. Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in United States. Urology 2008;71:531-5.
138. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994;23:1133-6.
139. Garland CF, Mohr SB, Gorham ED, et al. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med 2006;31:512-4.
140. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol 1995;142:608-11.
141. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-8.
142. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007;99:1594-602.
143. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989;2:1176-8.
144. Gorham ED, Garland CF, Garland FC, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007;32:210-6.
145. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
146. Otani T, Iwasaki M, Sasazuki S, et al. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J Cancer 2007;97:446-51.
147. Wu K, Feskanich D, Fuchs CS, et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007;99:1120-9.
148. Yin L, Grandi N, Raum E, et al. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009;30:113-25.
149. Tangrea J, Helzlsouer K, Pietinen P, et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 1997;8:615-25.
150. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011;128:1414-24.
151. Yin L, Grandi N, Raum E, et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010;46:2196-205.
152. Kisker O, Onizuka S, Becker CM, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40.
153. Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 2008;122:461-7.
154. Pacini S, Punzi T, Morucci G, et al. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res 2012;32:45-52.
155. Welsh J, Wietzke JA, Zinser GM, et al. Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003;133:2425S-33S.
156. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 2004;80:1721S-4S.
157. Lowe L, Hansen CM, Senaratne S, Colston KW. Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res 2003;164:99-110.
158. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002;9:45-59.
159. McCullough ML, Stevens VL, Diver WR, et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 2007;9:R9.
160. Abbas S, Linseisen J, Slanger T, et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 2008;17:1339-43.
161. Anderson LN, Cotterchio M, Cole DE, Knight JA. Vitamin Drelated genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011;20:1708-17.
162. Peehl DM, Skowronski RJ, Leung GK, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10.
163. Oades GM, Dredge K, Kirby RS, Colston KW. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 2002;90:607-16.
164. Gregory KJ, Zhao B, Bielenberg DR, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010;5:e13428.
165. Dimopoulos MA, Germenis A, Savides P, et al. Genetic markers in carcinoma of the prostate. Eur Urol 1984;10:315-16.
166. Ahn J, Albanes D, Berndt SI, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009;30:769-76.
167. Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 1995;4:655-9.
168. Poynter JN, Jacobs ET, Figueiredo JC, et al. Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2010;19:525-36.
169. Hibler EA, Hu C, Jurutka PW, et al. Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2012;21:368-75.
170. Zhou L, Zhang X, Chen X, et al. GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population. Int J Clin Exp Med 2012;5:72-9.
171. Flohil SC, De Vries E, Van Meurs JBJ, et al. Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas. Exp Dermat 2010;19:1103-5.
172. Niino M, Fukazawa T, Kikuchi S, Sasaki H. Therapeutic potential of vitamin D for multiple sclerosis. Curr Med Chem 2008;15: 499-505.
173. Niino M, Kikuchi S, Fukazawa T, et al. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J Neuroimmunol 2002;127:177-9.
174. Steckley JL, Dyment DA, Sadovnick AD, et al. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 2000;54:729-32.
175. Rithidech KN, Honikel L, Milazzo M, et al. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult Scler 2009;15:455-64.
176. Hollsberg P, Haahr S, Larsen PM, Fey SJ. MS and the groupspecific component. Acta Neurol Scand 1988;78:158-60.
177. Lindblom B, Wetterling G, Link H. Distribution of group-specific component subtypes in multiple sclerosis. Acta Neurol Scand 1988;78:443-4.
178. Simon KC, Munger KL, Xing Y, Ascherio A. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler 2010;16:133-8.
179. Orton SM, Ramagopalan SV, Para AE, et al. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci 2011;305:116-20.
180. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-49.
181. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated
182. Palma AS, De Carvalho M, Grammel N, et al. Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:339-49.
183. McGrath J. Hypothesis: is low prenatal vitamin D a riskmodifying factor for schizophrenia? Schizophr Res 1999;40: 173-7.
184. Lange V. Genetic markers for schizophrenic subgroups. Psychiatr Clin (Basel) 1982;15:133-44.
185. Papiha SS, Roberts DF, McLeish L. Group-specific component (Gc) subtypes and schizophrenia. Clin Genet 1982;22:321-6.
186. Saha N, Tsoi WF. Serum protein markers in Chinese schizophrenics- haptoglobin types and transferrin and group-specific component subtypes. Clin Genet 1990;37:54-8.
187. Beckman L, Beckman G, Perris C. Gc serum groups and schizophrenia. Clin Genet 1980;17:149-52.
188. Rudduck C, Franzen G, Hansson A, Rorsman B. Gc serum groups in schizophrenia. Hum Hered 1985;35:11-4.
189. Fananas L, Moral P, Marti Tusquets JL, Bertranpetit J. Genetic markers in schizophrenia: ACP1, ESD, TF and GC polymorphisms. Hum Hered 1990;40:136-40.
190. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-8.
191. Suzuki M, Yoshioka M, Hashimoto M, et al. 25-Hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Mov Disord 2012;27:264-71.
192. Milman N, Thymann M, Graudal N, Morling N. Plasma vitamin D-binding protein (GC) factors, immunoglobulin G heavy chain (GM) allotypes and immunoglobulin kappa light chain (KM1) allotype in patients with sarcoidosis and in healthy control subjects. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:97-100.
193. Tokuda N, Mano T, Levy RB. 1,25-Dihydroxyvitamin D3 antagonizes interferon-gamma-induced expression of class II major histocompatibility antigens on thyroid follicular and testicular Leydig cells. Endocrinology 1990;127:1419-27.
194. Thomasset M. [Vitamin D and the immune system]. Pathol Biol (Paris) 1994;42:163-72.
195. Pani MA, Regulla K, Segni M, et al. A polymorphism within the vitamin D-binding protein gene is associated with Graves' disease but not with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2002;87:2564-7.
196. Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study. Exp Clin Endocrinol Diabetes 2006;114:329-35.
197. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002;347:1860-6.
198. Davies PD. A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis. Tubercle 1985;66:301-6.
199. Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax 1985;40:187-90.
200. Grange JM, Davies PD, Brown RC, et al. A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis. Tubercle 1985;66:187-91.
201. Chan TY, Poon P, Pang J, et al. A study of calcium and vitamin D metabolism in Chinese patients with pulmonary tuberculosis. J Trop Med Hyg 1994;97:26-30.
202. Sasidharan PK, Rajeev E, Vijayakumari V. Tuberculosis and vitamin D deficiency. J Assoc Physicians India 2002;50:554-8.
203. Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn HJ. Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight. Thorax 2007;62:1003-7.
204. Gibney KB, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis 2008;46:443-6.
205. Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007;176:208-13.
206. Martineau AR, Leandro AC, Anderson ST, et al. Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. Eur Respir J 2010;35:1106-12.
207. Petrini M, Emerson DL, Galbraith RM. Linkage between surface immunoglobulin and cytoskeleton of B lymphocytes may involve Gc protein. Nature 1983;306:73-4.
208. Bahr GM, Eales LJ, Nye KE, et al. An association between Gc (vitamin D-binding protein) alleles and susceptibility to rheumatic fever. Immunology 1989;67:126-8.
209. Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol 2008;62:425-43.
210. Kuroda MJ. Macrophages: do they impact AIDS progression more than CD4 T cells? J Leukoc Biol 2010;87:569-73.
211. Yamamoto N, Ushijima N, Koga Y. Immunotherapy of HIVinfected patients with Gc protein-derived macrophage activating factor (GcMAF). J Med Virol 2009;81:16-26.
212. Pronk JC, Frants RR, Crusius B, et al. No predictive value of GC phenotypes for HIV infection and progression to AIDS. Hum Genet 1988;80:181-2.
213. Goudsmit J, de WF, Paul DA, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986;2:177-80.
214. Lange JM, Paul DA, Huisman HG, et al. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) 1986;293:1459-62.
215. de WF, Goudsmit J, Paul DA, et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) 1987;295:569-72.
216. Alonso A, Montesino M, Iturralde MJ, et al. GC subtyping and HIV infection in a Spanish population: no evidence of an association between GC subtypes and AIDS. Hum Hered 1990;40:34-7.
217. Cleve H, Weidinger S, Gurtler LG, Deinhardt F. AIDS: no association with the genetic systems GC (D-binding protein), ORM (orosomucoid=alpha-1-acid glycoprotein), and A2HS (alpha-2-HS-glycoprotein). Infection 1988;16:31-5.
218. Putkonen P, Albert J, Karlsson A, et al. Group specific component and susceptibility to HIV infection and progression to AIDS. Scand J Infect Dis 1988;20:11-4.
219. Eales LJ, Nye KE, Parkin JM, et al. Association of different allelic forms of group specific component with susceptibility to and clinical manifestation of human immunodeficiency virus infection. Lancet 1987;1:999-1002.
220. Nagasawa H, Sasaki H, Uto Y, et al. Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein. Anticancer Res 2004;24:3361-66.
221. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008;4:404-12.
222. Dong X, Lutz W, Schroeder TM, et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci USA 2005;102:16007-12.
223. Bondy B. Genetics in psychiatry: are the promises met? World J Biol Psychiatry 2011;12:81-8.
224. Cooper JD, Smyth DJ, Walker NM, et al. Inherited variation in vitamin d genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 2011;60:1624-31.
225. Hodge SE, Anderson CE, Neiswanger K, et al. Association studies between Type 1 (insulin-dependent) diabetes and 27 genetic markers: lack of association between Type 1 diabetes and Kidd blood group. Diabetologia 1983;25:343-7.
226. Eichner JE, Cauley JA, Ferrell RE, et al. Genetic variation in two bone-related proteins: is there an association with bone mineral density or skeletal size in postmenopausal women? Genet Epidemiol 1992;9:177-84.
227. Rosberger DF, Werner PA, Steinman R, et al. Group specific component (Gc) and HIV diseases. Dis Markers 1988;6:269-74.